CN1268743C - 编码细胞靶向部分和异源前体药物活化酶的基因构建体及其应用 - Google Patents

编码细胞靶向部分和异源前体药物活化酶的基因构建体及其应用 Download PDF

Info

Publication number
CN1268743C
CN1268743C CNB988049295A CN98804929A CN1268743C CN 1268743 C CN1268743 C CN 1268743C CN B988049295 A CNB988049295 A CN B988049295A CN 98804929 A CN98804929 A CN 98804929A CN 1268743 C CN1268743 C CN 1268743C
Authority
CN
China
Prior art keywords
gly
ala
ser
leu
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB988049295A
Other languages
English (en)
Chinese (zh)
Other versions
CN1255163A (zh
Inventor
S·C·埃默里
D·C·布拉凯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca UK Ltd
Syngenta Ltd
Original Assignee
Zeneca Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zeneca Ltd filed Critical Zeneca Ltd
Publication of CN1255163A publication Critical patent/CN1255163A/zh
Application granted granted Critical
Publication of CN1268743C publication Critical patent/CN1268743C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6899—Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/788—Of specified organic or carbon-based composition
    • Y10S977/802—Virus-based particle
    • Y10S977/803—Containing biological material in its interior
    • Y10S977/804—Containing nucleic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nanotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Medical Informatics (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
CNB988049295A 1997-05-10 1998-05-05 编码细胞靶向部分和异源前体药物活化酶的基因构建体及其应用 Expired - Fee Related CN1268743C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9709421.3 1997-05-10
GBGB9709421.3A GB9709421D0 (en) 1997-05-10 1997-05-10 Chemical compounds

Publications (2)

Publication Number Publication Date
CN1255163A CN1255163A (zh) 2000-05-31
CN1268743C true CN1268743C (zh) 2006-08-09

Family

ID=10812048

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB988049295A Expired - Fee Related CN1268743C (zh) 1997-05-10 1998-05-05 编码细胞靶向部分和异源前体药物活化酶的基因构建体及其应用

Country Status (23)

Country Link
US (1) US6339070B1 (https=)
EP (1) EP0979292B1 (https=)
JP (1) JP2001526539A (https=)
KR (1) KR100508136B1 (https=)
CN (1) CN1268743C (https=)
AT (1) ATE412755T1 (https=)
AU (1) AU734915B2 (https=)
BR (1) BR9808769A (https=)
CA (1) CA2286875A1 (https=)
DE (1) DE69840165D1 (https=)
ES (1) ES2314990T3 (https=)
GB (2) GB9709421D0 (https=)
HU (1) HUP0001931A3 (https=)
IL (1) IL132348A0 (https=)
MY (1) MY140975A (https=)
NO (1) NO995475L (https=)
NZ (1) NZ500014A (https=)
PL (1) PL337007A1 (https=)
RU (1) RU2218404C2 (https=)
SK (1) SK153599A3 (https=)
TR (1) TR199902731T2 (https=)
WO (1) WO1998051787A2 (https=)
ZA (1) ZA983931B (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9910077D0 (en) 1999-05-01 1999-06-30 Univ Manchester Chemical compounds
DE19946142A1 (de) * 1999-09-27 2001-03-29 Bundesrepublik Deutschland Let Gentransfer in humane Lymphocyten mittels retroviraler scFv-Zelltargeting Vektoren
GB0001653D0 (en) * 2000-01-26 2000-03-15 Astrazeneca Uk Ltd Chemical compound
GB0102239D0 (en) 2001-01-29 2001-03-14 Cancer Res Ventures Ltd Methods of chemical synthisis
WO2002094318A1 (en) * 2001-05-18 2002-11-28 University Of Southern California Vector for targeted delivery to cells
US7244592B2 (en) 2002-03-07 2007-07-17 Dyax Corp. Ligand screening and discovery
WO2003104425A2 (en) * 2002-06-07 2003-12-18 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Novel stable anti-cd22 antibodies
US20050107320A1 (en) * 2003-01-30 2005-05-19 Matthew During Methods and compositions for use in interventional pharmacogenomics
CA2524124C (en) 2003-04-30 2014-03-25 Uwe Zangemeister-Wittke Methods for treating cancer using an immunotoxin
JP4982183B2 (ja) * 2003-12-12 2012-07-25 ジェネンコー・インターナショナル・インク Ｃａｂ分子
RU2413731C2 (ru) 2004-04-09 2011-03-10 Чугаи Сейяку Кабусики Кайся Новые растворимые в воде пролекарства
US20060105941A1 (en) * 2004-11-12 2006-05-18 Allergan, Inc. Mixed antibiotic codrugs
TW200744603A (en) 2005-08-22 2007-12-16 Chugai Pharmaceutical Co Ltd Novel anticancer concomitant drug
CA2633756C (en) * 2005-12-21 2015-11-24 Micromet Ag Pharmaceutical antibody compositions with resistance to soluble cea
CA2684330A1 (en) * 2007-04-19 2008-10-30 Viventia Biotech Inc. Optimized nucleotide sequences of vb6-845 for expression of recombinant proteins
US8318472B2 (en) * 2007-09-27 2012-11-27 Viventia Biotechnologies Inc. Optimized nucleic acid sequences for the expression of VB4-845
WO2010019257A2 (en) 2008-08-13 2010-02-18 The Johns Hopkins University Prodrug activation in cancer cells using molecular switches
WO2010085665A2 (en) 2009-01-23 2010-07-29 Cedars-Sinai Medical Center Targeted delivery system
SG10201603411WA (en) * 2011-10-28 2016-07-28 Teva Pharmaceuticals Australia Pty Ltd Polypeptide constructs and uses thereof
CA2881582A1 (en) 2012-08-03 2014-02-06 Cedars-Sinai Medical Center Isolating traffic-enhancing mutants of drug delivery protein
US11117975B2 (en) 2013-04-29 2021-09-14 Teva Pharmaceuticals Australia Pty Ltd Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
WO2015048901A1 (en) 2013-10-02 2015-04-09 Viventia Bio Inc. Anti-epcam antibodies and methods of use
UA119352C2 (uk) 2014-05-01 2019-06-10 Тева Фармасьютикалз Острейліа Пті Лтд Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
CA2965414C (en) 2014-10-29 2024-01-09 Teva Pharmaceuticals Australia Pty Ltd Interferon .alpha.2.beta. variants
US10583198B2 (en) 2015-03-12 2020-03-10 Viventia Bio Inc. Dosing strategies for targeting EPCAM positive bladder cancer
EP3268040A4 (en) 2015-03-12 2018-09-12 Viventia Bio Inc. Methods of treatment for epcam positive bladder cancer
MX2022011805A (es) 2020-03-24 2023-01-11 Generation Bio Co Vectores de adn no virales y usos de estos para expresar agentes terapéuticos con factor ix.
AU2021244559A1 (en) 2020-03-24 2022-11-17 Generation Bio Co. Non-viral DNA vectors and uses thereof for expressing Gaucher therapeutics
WO2024040222A1 (en) 2022-08-19 2024-02-22 Generation Bio Co. Cleavable closed-ended dna (cedna) and methods of use thereof
CN119454938B (zh) * 2024-11-15 2025-07-25 广州骐骥生物科技有限公司 一种枸橼酸透析浓缩液及其制备方法
CN119564851B (zh) * 2024-12-05 2025-08-22 广州骐骥生物科技有限公司 一种冰醋酸透析浓缩液及其制备方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5632990A (en) * 1988-04-22 1997-05-27 Cancer Research Campaign Tech. Ltd. Treatment for tumors comprising conjugated antibody A5B7 and a prodrug
GB8809616D0 (en) * 1988-04-22 1988-05-25 Cancer Res Campaign Tech Further improvements relating to drug delivery systems
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
JP4041535B2 (ja) 1989-08-18 2008-01-30 オックスフォード バイオメディカ（ユーケー）リミテッド 標的細胞にベクター構造体を運搬する組換レトロウィルス
US6337209B1 (en) 1992-02-26 2002-01-08 Glaxo Wellcome Inc. Molecular constructs containing a carcinoembryonic antigen regulatory sequence
GB8919607D0 (en) 1989-08-30 1989-10-11 Wellcome Found Novel entities for cancer therapy
DE4106389A1 (de) * 1991-02-28 1992-09-03 Behringwerke Ag Fusionsproteine zur prodrug-aktivierung, ihre herstellung und verwendung
US5314995A (en) * 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
GB9014932D0 (en) * 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
GB2276169A (en) * 1990-07-05 1994-09-21 Celltech Ltd Antibodies specific for carcinoembryonic antigen
DE4110409C2 (de) 1991-03-29 1999-05-27 Boehringer Ingelheim Int Neue Protein-Polykation-Konjugate
WO1993019163A1 (en) 1992-03-18 1993-09-30 Yeda Research And Development Co, Ltd. Chimeric receptor genes and cells transformed therewith
GB9314960D0 (en) * 1992-07-23 1993-09-01 Zeneca Ltd Chemical compounds
ATE245703T1 (de) 1992-09-22 2003-08-15 Biofocus Discovery Ltd Rekombinante viren, die an ihrer äusseren oberfläche ein nichtvirales polypeptid präsentieren
GB9223084D0 (en) 1992-11-04 1992-12-16 Imp Cancer Res Tech Compounds to target cells
US5464758A (en) * 1993-06-14 1995-11-07 Gossen; Manfred Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
GB9323008D0 (en) 1993-11-05 1994-01-05 Connors Thomas Improvements relating to cancer therapy
GB9324807D0 (en) * 1993-12-03 1994-01-19 Cancer Res Campaign Tech Tumour antibody
GB9415167D0 (en) 1994-07-27 1994-09-14 Springer Caroline J Improvements relating to cancer therapy
GB9423367D0 (en) 1994-11-18 1995-01-11 Wellcome Found Enzyme prodrug therapy
RU2189251C2 (ru) * 1994-12-23 2002-09-20 Зенека Лимитед Химические соединения
CN1193278A (zh) * 1995-08-16 1998-09-16 曾尼卡有限公司 化合物
GB9523703D0 (en) 1995-11-20 1996-01-24 Wellcome Found Enzyme prodrug thearapy
GB9601640D0 (en) 1996-01-26 1996-03-27 Cancer Res Campaign Tech Ligand directed enzyme prodrug therapy
SK150298A3 (en) * 1996-05-04 1999-04-13 Zeneca Ltd Monoclonal antibody to cea, conjugates comprising said antibody, and their therapeutic use in an adept system
EP1717248A1 (en) 1997-06-04 2006-11-02 Oxford Biomedica (UK) Limited Tumor targeted vector

Also Published As

Publication number Publication date
WO1998051787A3 (en) 1999-04-01
NO995475L (no) 2000-01-07
NZ500014A (en) 2001-08-31
GB9922815D0 (en) 1999-11-24
AU7225498A (en) 1998-12-08
ATE412755T1 (de) 2008-11-15
DE69840165D1 (de) 2008-12-11
PL337007A1 (en) 2000-07-31
HUP0001931A3 (en) 2003-10-28
CA2286875A1 (en) 1998-11-19
KR20010012441A (ko) 2001-02-15
US6339070B1 (en) 2002-01-15
IL132348A0 (en) 2001-03-19
GB9709421D0 (en) 1997-07-02
BR9808769A (pt) 2000-08-01
ZA983931B (en) 1998-11-10
KR100508136B1 (ko) 2005-08-10
HUP0001931A2 (hu) 2000-09-28
NO995475D0 (no) 1999-11-09
JP2001526539A (ja) 2001-12-18
SK153599A3 (en) 2000-06-12
WO1998051787A2 (en) 1998-11-19
CN1255163A (zh) 2000-05-31
ES2314990T3 (es) 2009-03-16
AU734915B2 (en) 2001-06-28
EP0979292B1 (en) 2008-10-29
TR199902731T2 (xx) 2000-06-21
EP0979292A2 (en) 2000-02-16
RU2218404C2 (ru) 2003-12-10
MY140975A (en) 2010-02-12
GB2338484B (en) 2001-11-07
GB2338484A (en) 1999-12-22

Similar Documents

Publication Publication Date Title
CN1268743C (zh) 编码细胞靶向部分和异源前体药物活化酶的基因构建体及其应用
CN1224712C (zh) 载体
CN1217956C (zh) 可溶性单链t细胞受体蛋白
CN1241944C (zh) 抗人白介素－5受体α链的抗体
CN1229391C (zh) 涉及α6β4整联蛋白的人胃肠上皮肿瘤抗原的抗体
CN1163509C (zh) 刺激神经和肾生长的RET配体(RetL)
CN1423660A (zh) 抗体
CN1187374C (zh) 人源化的特异于人4－1bb的抗体和含有它的药物组合物
HK1042503A1 (zh) 表达以及分泌制管张素和endostatin的免疫融合物
CN1604966A (zh) 直接靶定的结合蛋白
CN1095677C (zh) 化合物
CN1606453A (zh) Cripto阻断抗体及其用途
CA2250579A1 (en) Monoclonal antibody to cea, conjugates comprising said antibody, and their therapeutic use in an adept system
CN1636017A (zh) 含有蛋白酶激活序列的气单胞菌溶素原及其在前列腺癌治疗中的使用方法
CN1378595A (zh) 作为zalpha受体之配体的人细胞因子及其用途
CN101076542A (zh) 特异性针对肝细胞癌和其他癌的抗体及其用途
CN1151184A (zh) 对细胞周期非依赖的神经胶质瘤表面抗原特异的人单克隆抗体
CN1649901A (zh) 人癌胚抗原(cea)的特异性抗体片段
US6838446B1 (en) Vector for expression of GPI-enzyme hybrid
CZ396599A3 (cs) Genový konstrukt, který kóduje část zaměřující buňku a enzym aktivující proléčivo, pro použití jako léčivo
MXPA99010224A (en) Chemical compounds
CN1753991A (zh) 单克隆抗体及编码该单克隆抗体的基因、杂交瘤、药物组合物和诊断试剂
CN1913913A (zh) Cab分子
HK1078589A1 (en) Anti-human tenascin monoclonal antibody
HK1078589B (en) Anti-human tenascin monoclonal antibody

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
ASS Succession or assignment of patent right

Owner name: ASTRAZENECA (UK) LIMITED

Free format text: FORMER OWNER: SIGENTIS CO., LTD.

Effective date: 20070202

C41 Transfer of patent application or patent right or utility model
C56 Change in the name or address of the patentee

Owner name: SIGENTIS CO., LTD.

Free format text: FORMER NAME OR ADDRESS: ZENECA LTD

CP03 Change of name, title or address

Address after: surrey

Patentee after: SYNGENTA LTD.

Address before: England

Patentee before: ZENECA Ltd.

TR01 Transfer of patent right

Effective date of registration: 20070202

Address after: London, England

Patentee after: ASTRAZENECA UK LTD.

Address before: surrey

Patentee before: SYNGENTA LTD.

C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20060809

Termination date: 20100505